These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 21569543)

  • 1. Incidence of atrial fibrillation in patients with either heart failure or acute myocardial infarction and left ventricular dysfunction: a cohort study.
    Schmiegelow MD; Pedersen OD; Køber L; Seibæk M; Abildstrøm SZ; Torp-Pedersen C
    BMC Cardiovasc Disord; 2011 May; 11():19. PubMed ID: 21569543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
    Torp-Pedersen C; Møller M; Bloch-Thomsen PE; Køber L; Sandøe E; Egstrup K; Agner E; Carlsen J; Videbaek J; Marchant B; Camm AJ
    N Engl J Med; 1999 Sep; 341(12):857-65. PubMed ID: 10486417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Danish Investigations of Arrhythmia and Mortality ON Dofetilide.
    Mosller M
    Clin Cardiol; 1997 Aug; 20(8):704-10. PubMed ID: 9259163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of QTc interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide.
    Brendorp B; Elming H; Jun L; Køber L; Torp-Pedersen C;
    Clin Cardiol; 2003 May; 26(5):219-25. PubMed ID: 12769249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) study.
    Pedersen OD; Brendorp B; Elming H; Pehrson S; Køber L; Torp-Pedersen C
    Card Electrophysiol Rev; 2003 Sep; 7(3):220-4. PubMed ID: 14739717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide.
    Pedersen HS; Elming H; Seibaek M; Burchardt H; Brendorp B; Torp-Pedersen C; Køber L;
    Am J Cardiol; 2007 Sep; 100(5):876-80. PubMed ID: 17719337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial.
    Køber L; Bloch Thomsen PE; Møller M; Torp-Pedersen C; Carlsen J; Sandøe E; Egstrup K; Agner E; Videbaek J; Marchant B; Camm AJ;
    Lancet; 2000 Dec; 356(9247):2052-8. PubMed ID: 11145491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy.
    Pedersen OD; Bagger H; Keller N; Marchant B; Køber L; Torp-Pedersen C
    Circulation; 2001 Jul; 104(3):292-6. PubMed ID: 11457747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes and Characteristics With Dofetilide in Atrial Fibrillation Patients Considered for Implantable Cardioverter-Defibrillator.
    Koene RJ; Menon V; Cantillon DJ; Dresing TJ; Martin DO; Kanj M; Saliba WI; Tarakji KG; Baranowski B; Hussein AA; Tchou PJ; Bhargava M; Callahan TD; Rickard JW; Niebauer MJ; Chung MK; Varma N; Wilkoff BL; Lindsay BD; Wazni OM
    Circ Arrhythm Electrophysiol; 2020 Jul; 13(7):e008168. PubMed ID: 32538135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dofetilide to patients with heart failure and left ventricular dysfunction].
    Torp-Pedersen CT; Møller M; Bloch-Thomsen PE; Køber L; Sandøe E; Egstrup K; Agner E; Carlsen JE; Videbaek J
    Ugeskr Laeger; 2000 Oct; 162(44):5948-53. PubMed ID: 11094565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure.
    Brendorp B; Elming H; Jun L; Køber L; Torp-Pedersen C;
    Eur J Heart Fail; 2002 Mar; 4(2):201-6. PubMed ID: 11959050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.
    O'Meara E; Khairy P; Blanchet MC; de Denus S; Pedersen OD; Levesque S; Talajic M; Ducharme A; White M; Racine N; Rouleau JL; Tardif JC; Roy D;
    Circ Heart Fail; 2012 Sep; 5(5):586-93. PubMed ID: 22798522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qtc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide.
    Brendorp B; Elming H; Jun L; Køber L; Malik M; Jensen GB; Torp-Pedersen C;
    Circulation; 2001 Mar; 103(10):1422-7. PubMed ID: 11245647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dofetilide in patients with chronic heart failure and left ventricular dysfunction].
    Latini R
    Ital Heart J Suppl; 2000 Mar; 1(3):427-8. PubMed ID: 10815277
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study.
    Singh SN
    Card Electrophysiol Rev; 2003 Sep; 7(3):225-8. PubMed ID: 14739718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Left Ventricular Function and Heart Failure Symptoms on Outcomes Post Ablation of Atrial Fibrillation in Heart Failure: CASTLE-AF Trial.
    Sohns C; Zintl K; Zhao Y; Dagher L; Andresen D; Siebels J; Wegscheider K; Sehner S; Boersma L; Merkely B; Pokushalov E; Sanders P; Schunkert H; Bänsch D; Mahnkopf C; Brachmann J; Marrouche NF
    Circ Arrhythm Electrophysiol; 2020 Oct; 13(10):e008461. PubMed ID: 32903044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ; Markham A
    Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival after withdrawal of dofetilide in patients with congestive heart failure and a short baseline QTc interval; a follow-up on the Diamond-CHF QT substudy.
    Brendorp B; Torp-Pedersen C; Elming H; Køber L
    Eur Heart J; 2003 Feb; 24(3):274-9. PubMed ID: 12590905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular outcomes among elderly patients with heart failure and coronary artery disease and without atrial fibrillation: a retrospective cohort study.
    Zhao Q; Wang L; Kurlansky PA; Schein J; Baser O; Berger JS
    BMC Cardiovasc Disord; 2019 Jan; 19(1):19. PubMed ID: 30646855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.